PT - JOURNAL ARTICLE AU - Yu Zuo AU - Srilakshmi Yalavarthi AU - Sherwin Navaz AU - Claire Hoy AU - Hui Shi AU - Alyssa Harbaugh AU - Kelsey Gockman AU - Melanie Zuo AU - Jacqueline A. Madison AU - Yogendra Kanthi AU - Jason S. Knight TI - Autoantibodies stabilize neutrophil extracellular traps in COVID-19 AID - 10.1101/2021.03.31.21254692 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.31.21254692 4099 - http://medrxiv.org/content/early/2021/04/05/2021.03.31.21254692.short 4100 - http://medrxiv.org/content/early/2021/04/05/2021.03.31.21254692.full AB - The release of neutrophil extracellular traps (NETs) by hyperactive neutrophils is recognized to play an important role in the thromboinflammatory milieu inherent to severe presentations of COVID-19. At the same time, a variety of functional autoantibodies have been observed in individuals with severe COVID-19 where they likely contribute to immunopathology. Here, we aimed to determine the extent to which autoantibodies might target NETs in COVID-19 and, if detected, to elucidate their potential functions and clinical associations. We measured global anti-NET activity in 171 individuals hospitalized with COVID-19 alongside 48 healthy controls. We found high anti-NET activity in the IgG and IgM fractions of approximately 40% and 50% of patients, respectively. There was a strong correlation between anti-NET IgG and anti-NET IgM, with high anti-NET antibody levels in general associating with circulating markers of NETs such as myeloperoxidase-DNA complexes and calprotectin. Clinically, anti-NET antibodies tracked with impaired oxygenation efficiency and elevated levels of circulating D-dimer. Furthermore, patients who required mechanical ventilation had higher levels of anti-NET antibodies than those who did not require oxygen supplementation. Mechanistically, anti-NET antibodies of the IgG isotype impaired the ability of DNases in healthy serum to degrade NETs. In summary, these data reveal high levels of anti-NET antibodies in individuals hospitalized with COVID-19, where they likely impair NET clearance and thereby potentiate SARS-CoV-2 mediated thromboinflammation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYZ was supported by career development grants from the Rheumatology Research Foundation and APS ACTION. JAM was partially supported by the VA Healthcare System. YK was supported by the Intramural Research Program of the NIH and NHLBI, Lasker Foundation, Falk Medical Research Trust Catalyst Award, and the JOBST-American Venous Forum Award. JSK was supported by grants from the NIH (R01HL115138), Lupus Research Alliance, Rheumatology Research Foundation, and Burroughs Wellcome Fund. YK and JSK were supported by the University of Michigan Frankel Cardiovascular Center Ignitor Award and the A. Alfred Taubman Medical Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study complied with all relevant ethical regulations and was approved by the University of Michigan IRB (HUM00179409).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript and supplement.